endogenous retrovirus group MER61 member 1Genealiases: C1orf99 · TP53LC07
Q-omics provides the consensus-scored ERVMER61-1 profile across patient tissues and cancer cell-line models. ERVMER61-1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ERVMER61-1 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, ERVMER61-1 RNA expression shows 8,040 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where ERVMER61-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERVMER61-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERVMER61-1 survival associations across molecular data types. ERVMER61-1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERVMER61-1 RNA expression–survival associations across cancer types. High ERVMER61-1 expression shows unfavorable associations in KIRP, BRCA, CESC, LIHC and KICH, but favorable associations in UVM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ERVMER61-1 RNA expression.
This table summarizes ERVMER61-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ERVMER61-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERVMER61-1 shows higher tumor expression in COAD, LUSC, LIHC, UCEC, THCA and HNSC. The COAD box plot shows higher ERVMER61-1 RNA expression in tumor versus normal tissue (log2 FC = +0.347, t-test p = .006).
This table shows molecular features associated with ERVMER61-1 in patient tissues and cancer cell lines. In patient samples, ERVMER61-1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
